

BCCA Protocol Summary for Palliative Therapy of Extensive Small Cell Lung Cancer (SCLC) with Oral Etoposide (Interim Version)

Protocol Code: LUPOE

Tumour Group: Lung

Contact Physician: Dr. Nevin Murray

ELIGIBILITY:

- Extensive SCLC patients refusing or unsuitable for combination chemotherapy
- Relapsed SCLC after prior chemotherapy with disease-free interval > 3 months

TESTS:

- Baseline: CBC & differential, platelets
- Before each treatment: CBC & differential, platelets

PREMEDICATIONS:

- See Antiemetic guidelines for non-emetogenic chemotherapy protocols. Antiemetics are not usually required. Prescribe according to patient specific symptoms.

TREATMENT:

Drug	Dose	BCCA Administration Guidelines
Etoposide	50 mg PO BID x 7 days	PO

- Repeat every 21 days x 4-6 cycles

DOSE MODIFICATIONS:

1. Hematology

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	Etoposide dose
≥ 2.0	and	≥ 100	100%
< 2.0	or	< 100	Delay

2. Neutropenic Sepsis: reassess subsequent doses

PRECAUTIONS:

1. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

Contact Dr. Nevin Murray or tumor group delegate @ (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date Revised: 11 Aug 1999